AIDS Alert Archives – November 1, 2011
November 1, 2011
View Issues
-
Neurological disorders strikingly high among HIV/AIDS patients
New research suggests that roughly half of HIV patients might have some neurocognitive impairment, although most of this might be asymptomatic or mild. -
Key marker speeds up neuro-brain decline
Researchers continue to study the neurological processes impacting HIV-associated neurocognitive disorder (HAND), finding most recently that an inflammatory marker called osteopontin stimulates HIV replication and remains in the central nervous system despite antiretroviral therapy. -
Exposure to violence ups HIV risk for girls
African-American girls from low-income neighborhoods who have had childhood violence exposure are significantly more likely to engage in high-risk sexual activities, researchers found. -
HIV and health care: The good, bad & ugly
In selected data analysis for 2007, most people with HIV infection who were receiving medical care were taking antiretroviral therapy and had some form of health insurance or coverage, the Centers for Disease Control and Prevention reports. -
'Lab on a chip' as screening tool option
Field test results of an integrated microfluidic-based diagnostic device indicate that the potential -
FDA Notifications
On Aug. 10, 2011, the Food and Drug Administration (FDA) approved Complera, a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of Complera is one tablet, containing 200mg/25mg/300mg of FTC/RPV/TDF, once daily, taken orally with a meal. -
The Joint Commission Update for Infection Control: Joint Commission: New year will usher in new CAUTI prevention requirements
The Joint Commission's new National Patient Safety Goal (NPSG) on preventing indwelling catheter-associated urinary tract infections which emphasizes prompt removal of unnecessary devices and surveillance for CAUTIs is effective January 1, 2012 for hospitals. -
The Joint Commission Update for Infection Control: Follow the fab four
The elements of performance for the CAUTI prevention safety goal are as follows: -
The Joint Commission Update for Infection Control: VA programs cuts CLABSIs by >50%
The Joint Commission targets central lineassociated bloodstream infections in its 2011 national patient safety goals, with NPSG.07.04.01 calling for hospitals to "implement evidence-based practices to prevent (CLABSIs)." -
The Joint Commission Update for Infection Control: JC Q&A: Active testing for MRSA
The Joint Commission recently posted the following answer to a frequently asked question on screening for methicillin-resistant Staphylococcus aureus (MRSA).